204 related articles for article (PubMed ID: 18026137)
1. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase.
Banerjee T; Duhadaway JB; Gaspari P; Sutanto-Ward E; Munn DH; Mellor AL; Malachowski WP; Prendergast GC; Muller AJ
Oncogene; 2008 May; 27(20):2851-7. PubMed ID: 18026137
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.
Muller AJ; DuHadaway JB; Donover PS; Sutanto-Ward E; Prendergast GC
Nat Med; 2005 Mar; 11(3):312-9. PubMed ID: 15711557
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors.
Gaspari P; Banerjee T; Malachowski WP; Muller AJ; Prendergast GC; DuHadaway J; Bennett S; Donovan AM
J Med Chem; 2006 Jan; 49(2):684-92. PubMed ID: 16420054
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model.
Yoshida N; Ino K; Ishida Y; Kajiyama H; Yamamoto E; Shibata K; Terauchi M; Nawa A; Akimoto H; Takikawa O; Isobe K; Kikkawa F
Clin Cancer Res; 2008 Nov; 14(22):7251-9. PubMed ID: 19010841
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.
Hou DY; Muller AJ; Sharma MD; DuHadaway J; Banerjee T; Johnson M; Mellor AL; Prendergast GC; Munn DH
Cancer Res; 2007 Jan; 67(2):792-801. PubMed ID: 17234791
[TBL] [Abstract][Full Text] [Related]
6. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD
Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770
[TBL] [Abstract][Full Text] [Related]
7. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.
Lee SY; Choi HK; Lee KJ; Jung JY; Hur GY; Jung KH; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH
J Immunother; 2009 Jan; 32(1):22-8. PubMed ID: 19307990
[TBL] [Abstract][Full Text] [Related]
8. Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.
Dolušić E; Larrieu P; Blanc S; Sapunaric F; Norberg B; Moineaux L; Colette D; Stroobant V; Pilotte L; Colau D; Ferain T; Fraser G; Galleni M; Frère JM; Masereel B; Van den Eynde B; Wouters J; Frédérick R
Bioorg Med Chem; 2011 Feb; 19(4):1550-61. PubMed ID: 21269836
[TBL] [Abstract][Full Text] [Related]
9. Marrying immunotherapy with chemotherapy: why say IDO?
Muller AJ; Prendergast GC
Cancer Res; 2005 Sep; 65(18):8065-8. PubMed ID: 16166276
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.
Yue EW; Douty B; Wayland B; Bower M; Liu X; Leffet L; Wang Q; Bowman KJ; Hansbury MJ; Liu C; Wei M; Li Y; Wynn R; Burn TC; Koblish HK; Fridman JS; Metcalf B; Scherle PA; Combs AP
J Med Chem; 2009 Dec; 52(23):7364-7. PubMed ID: 19507862
[TBL] [Abstract][Full Text] [Related]
11. Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression.
Liu H; Liu L; Liu K; Bizargity P; Hancock WW; Visner GA
J Immunol; 2009 Jul; 183(2):1022-31. PubMed ID: 19564344
[TBL] [Abstract][Full Text] [Related]
12. Blockade of indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock.
Jung ID; Lee MG; Chang JH; Lee JS; Jeong YI; Lee CM; Park WS; Han J; Seo SK; Lee SY; Park YM
J Immunol; 2009 Mar; 182(5):3146-54. PubMed ID: 19234212
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.
Munn DH
Curr Opin Immunol; 2006 Apr; 18(2):220-5. PubMed ID: 16460921
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate.
Muller AJ; DuHadaway JB; Jaller D; Curtis P; Metz R; Prendergast GC
Cancer Res; 2010 Mar; 70(5):1845-53. PubMed ID: 20160032
[TBL] [Abstract][Full Text] [Related]
15. Isosteric probes provide structural requirements essential for detoxification of the phytoalexin brassinin by the fungal pathogen Leptosphaeria maculans.
Pedras MS; Jha M; Minic Z; Okeola OG
Bioorg Med Chem; 2007 Sep; 15(18):6054-61. PubMed ID: 17616463
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of human indoleamine 2,3-dioxygenase identified with a target-based screen in yeast.
Vottero E; Balgi A; Woods K; Tugendreich S; Melese T; Andersen RJ; Mauk AG; Roberge M
Biotechnol J; 2006 Mar; 1(3):282-8. PubMed ID: 16897708
[TBL] [Abstract][Full Text] [Related]
17. Accelerated rejection of the second transplants of immunogenic tumor in mice under inhibition of indoleamine 2,3-dioxygenase activity by ethyl pyruvate.
Vasilyeva ED; Kaledin V; Nikolin VP; Popova NA; Kirilyuk IA; Grigor'ev IA
Exp Oncol; 2012; 34(1):66-8. PubMed ID: 22453153
[TBL] [Abstract][Full Text] [Related]
18. Isobrassinin and its analogues: novel types of antiproliferative agents.
Csomós P; Zupkó I; Réthy B; Fodor L; Falkay G; Bernáth G
Bioorg Med Chem Lett; 2006 Dec; 16(24):6273-6. PubMed ID: 16997552
[TBL] [Abstract][Full Text] [Related]
19. Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
Dolusić E; Larrieu P; Moineaux L; Stroobant V; Pilotte L; Colau D; Pochet L; Van den Eynde B; Masereel B; Wouters J; Frédérick R
J Med Chem; 2011 Aug; 54(15):5320-34. PubMed ID: 21726069
[TBL] [Abstract][Full Text] [Related]
20. Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice.
Yang S; Li X; Hu F; Li Y; Yang Y; Yan J; Kuang C; Yang Q
J Med Chem; 2013 Nov; 56(21):8321-31. PubMed ID: 24099220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
